https://openalex.org/T12255
This cluster of papers focuses on the immunogenicity of biosimilar therapeutics, including the validation of bioanalytical methods for assessing immunogenicity, the impact of manufacturing changes on immunogenicity, and the clinical outcomes and safety of switching from reference biologics to biosimilars. The use of dried blood spots for bioanalysis and the regulatory considerations for biosimilars are also prominent topics within this cluster.
@prefix oasubfields: <https://openalex.org/subfields/> .
@prefix openalex: <https://lambdamusic.github.io/openalex-hacks/ontology/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
<https://openalex.org/T12255> a skos:Concept ;
rdfs:label "Immunogenicity of Biosimilar Therapeutics in Drug Development"@en ;
rdfs:isDefinedBy openalex: ;
owl:sameAs <https://en.wikipedia.org/wiki/Biosimilar>,
<https://openalex.org/T12255> ;
skos:broader oasubfields:2403 ;
skos:definition "This cluster of papers focuses on the immunogenicity of biosimilar therapeutics, including the validation of bioanalytical methods for assessing immunogenicity, the impact of manufacturing changes on immunogenicity, and the clinical outcomes and safety of switching from reference biologics to biosimilars. The use of dried blood spots for bioanalysis and the regulatory considerations for biosimilars are also prominent topics within this cluster."@en ;
skos:inScheme openalex: ;
skos:prefLabel "Immunogenicity of Biosimilar Therapeutics in Drug Development"@en ;
openalex:cited_by_count 215614 ;
openalex:works_count 30384 .